Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gynecologic Cancers
•
Endometrial Cancer
For a recurrent, MSI-H endometrial cancer, do you usually treat with Pembrolizumab alone or in combination with Lenvatinib?
Answer from: at Community Practice
Alone.
Sign in or Register to read more
8655
Related Questions
When do you consider adjuvant chemotherapy and/or RT for stage I-III high-grade uterine sarcomas s/p resection?
Do you recommend a completion hysterectomy to patients who undergo primary radiation for endometrial cancer (presuming they are now a surgical candidate)?
Do you offer resection of oligometastatic disease for patients with recurrent uterine serous carcinoma within the pelvis following initial treatment with adjuvant chemotherapy and vaginal cuff brachytherapy?
How would you manage a patient in her 50s with FIGO IA clear cell carcinoma of the endometrium with extensive LVSI and ITCs in an obturator node after 6 cycles of carbo/taxol?
What are your top takeaways in Gynecologic Cancers from ASCO 2023?
If you recommend chemotherapy for early-stage uterine serous carcinoma, do you prefer 3 or 6 cycles?
How do you manage a patient with widely metastatic serous endometrial cancer whose disease is stable after completion of 6 cycles of chemotherapy + immunotherapy?
What are your image guidance instructions for post-op endometrial cancer EBRT?
How would you manage a POLE mutated, p53 abnormal IA myoinvasive carcinosarcoma of the endometrium with no LVSI?
What is your preferred first line systemic treatment for recurrent, metastatic, low grade, ER/PR+ pMMR endometrioid endometrial carcinoma?